{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T22:45:03Z","timestamp":1790635503889,"version":"4.1.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T00:00:00Z","timestamp":1765411200000},"content-version":"vor","delay-in-days":163,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lipidjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.jacl.2025.04.200","type":"journal-article","created":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T17:34:16Z","timestamp":1746725656000},"page":"819-826","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Evaluation of lipid-lowering therapy in patients with elevated lipoprotein(a) levels"],"prefix":"10.1016","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4272-8721","authenticated-orcid":false,"given":"Michael S.","family":"Kelly","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9912-4924","authenticated-orcid":false,"given":"Ruth N.","family":"Jeminiwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatima","family":"Gohar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-7126-0751","authenticated-orcid":false,"given":"Mario","family":"Fanous","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-1269-359X","authenticated-orcid":false,"given":"Pablo","family":"Ramirez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7560-9521","authenticated-orcid":false,"given":"Dave L.","family":"Dixon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"39","key":"10.1016\/j.jacl.2025.04.200_bib0001","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1093\/eurheartj\/ehac361","article-title":"Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement","volume":"43","author":"Kronenberg","year":"2022","journal-title":"Eur Heart J"},{"issue":"3","key":"10.1016\/j.jacl.2025.04.200_bib0002","doi-asserted-by":"crossref","first-page":"e308","DOI":"10.1016\/j.jacl.2024.03.001","article-title":"A focused update to the 2019 NLA scientific statement on use of lipoprotein(a) in clinical practice","volume":"18","author":"Koschinsky","year":"2024","journal-title":"J Clin Lipidol"},{"issue":"10","key":"10.1016\/j.jacl.2025.04.200_bib0003","article-title":"Association of lipoprotein (a) and standard modifiable cardiovascular risk factors with incident myocardial infarction: the Mass General Brigham Lp(a) Registry","volume":"13","author":"Shiyovich","year":"2024","journal-title":"J Am Heart Assoc Cardiovasc Cerebrovasc Dis"},{"issue":"9","key":"10.1016\/j.jacl.2025.04.200_bib0004","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.jacc.2023.12.031","article-title":"Lipoprotein(a) and major adverse cardiovascular events in patients with or without baseline atherosclerotic cardiovascular disease","volume":"83","author":"Berman","year":"2024","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"10.1016\/j.jacl.2025.04.200_bib0005","doi-asserted-by":"crossref","first-page":"e77","DOI":"10.1016\/j.jacl.2022.08.007","article-title":"Use of Lipoprotein(a) in clinical practice: a biomarker whose time has come. A scientific statement from the National Lipid Association","volume":"16","author":"Wilson","year":"2022","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2025.04.200_bib0006","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajpc.2024.100651","article-title":"High lipoprotein(a): actionable strategies for risk assessment and mitigation","volume":"18","author":"Reyes-Soffer","year":"2024","journal-title":"Am J Prev Cardiol"},{"issue":"8","key":"10.1016\/j.jacl.2025.04.200_bib0007","first-page":"1129","article-title":"2021 Canadian Cardiovascular Society Guidelines for the management of dyslipidemia for the prevention of Cardiovascular disease in adults","volume":"37","author":"Pearson","year":"2021","journal-title":"Can J Cardiol"},{"issue":"1","key":"10.1016\/j.jacl.2025.04.200_bib0008","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular riskThe Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"issue":"24","key":"10.1016\/j.jacl.2025.04.200_bib0009","doi-asserted-by":"crossref","first-page":"e285","DOI":"10.1016\/j.jacc.2018.11.003","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the Management of blood cholesterol","volume":"73","author":"Grundy","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"10.1016\/j.jacl.2025.04.200_bib0010","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.4158\/CS-2020-0490","article-title":"Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the management of Dyslipidemia and Prevention of Cardiovascular Disease Algorithm \u2013 2020 Executive summary","volume":"26","author":"Handelsman","year":"2020","journal-title":"Endocr Pract"},{"issue":"3","key":"10.1016\/j.jacl.2025.04.200_bib0011","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.123.033562","article-title":"Aspirin and cardiovascular risk in individuals with elevated lipoprotein(a): the multi-ethnic study of atherosclerosis","volume":"13","author":"Bhatia","year":"2024","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jacl.2025.04.200_bib0012","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajpc.2024.100674","article-title":"Aspirin use for primary prevention among US adults with and without elevated lipoprotein(a)","volume":"18","author":"Razavi","year":"2024","journal-title":"Am J Prev Cardiol"},{"issue":"10","key":"10.1016\/j.jacl.2025.04.200_bib0013","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1002\/phar.2851","article-title":"Role of lipoprotein(a) in atherosclerotic cardiovascular disease: a review of current and emerging therapies","volume":"43","author":"Alhomoud","year":"2023","journal-title":"Pharmacotherapy"},{"issue":"21","key":"10.1016\/j.jacl.2025.04.200_bib0014","doi-asserted-by":"crossref","DOI":"10.3390\/ijms242115531","article-title":"Changes in lipoprotein(a) levels in people after ST elevation myocardial infarction\u2014the STEMI-lipids study","volume":"24","author":"Sourij","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"2","key":"10.1016\/j.jacl.2025.04.200_bib0015","doi-asserted-by":"crossref","DOI":"10.1093\/ehjopen\/oead035","article-title":"Lipoprotein(a) concentrations in acute myocardial infarction patients are not indicative of levels at six month follow-up","volume":"3","author":"Ziogos","year":"2023","journal-title":"Eur Heart J Open"},{"key":"10.1016\/j.jacl.2025.04.200_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajpc.2023.100478","article-title":"Contemporary patterns of lipoprotein(a) testing and associated clinical care and outcomes","volume":"14","author":"Kelsey","year":"2023","journal-title":"Am J Prev Cardiol"},{"key":"10.1016\/j.jacl.2025.04.200_bib0017","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.atherosclerosis.2023.01.014","article-title":"Trends and consequences of lipoprotein(a) testing: cross-sectional and longitudinal health insurance claims database analyses","volume":"367","author":"St\u00fcrzebecher","year":"2023","journal-title":"Atherosclerosis"},{"issue":"18","key":"10.1016\/j.jacl.2025.04.200_bib0018","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.123.031255","article-title":"Lipoprotein(a) testing trends in a large academic health system in the United States","volume":"12","author":"Bhatia","year":"2023","journal-title":"J Am Heart Assoc"},{"issue":"10155","key":"10.1016\/j.jacl.2025.04.200_bib0019","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/S0140-6736(18)31652-0","article-title":"Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials","volume":"392","author":"Willeit","year":"2018","journal-title":"The Lancet"},{"issue":"16","key":"10.1016\/j.jacl.2025.04.200_bib0020","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1016\/j.jacc.2024.02.031","article-title":"Lipoprotein(a) and long-term cardiovascular risk in a multi-ethnic pooled prospective cohort","volume":"83","author":"Wong","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2025.04.200_bib0021","article-title":"Traditional risk factors, optimal cardiovascular health, and elevated lipoprotein(a)","author":"Razavi","year":"2024","journal-title":"Eur J Prev Cardiol."},{"issue":"6","key":"10.1016\/j.jacl.2025.04.200_bib0022","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.jacl.2023.09.009","article-title":"Frequency of lipoprotein(a) measurements in patients with or at risk of cardiovascular disease","volume":"17","author":"Upadhyaya","year":"2023","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2025.04.200_bib0023","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajpc.2024.100872","article-title":"Temporal trends in lipoprotein(a) testing among United States veterans from 2014 to 2023","volume":"20","author":"Gomez","year":"2024","journal-title":"Am J Prev Cardiol"},{"key":"10.1016\/j.jacl.2025.04.200_bib0024","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajpc.2024.100721","article-title":"Low prevalence of testing for apolipoprotein B and lipoprotein(a) in the real world","volume":"19","author":"Murdock","year":"2024","journal-title":"Am J Prev Cardiol"},{"issue":"6","key":"10.1016\/j.jacl.2025.04.200_bib0025","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.jacl.2023.09.016","article-title":"Prevalence of lipoprotein(a) measurement in patients with or at risk of cardiovascular disease","volume":"17","author":"Panza","year":"2023","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2025.04.200_bib0026","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacl.2024.07.012","article-title":"Attitudes and barriers to lipoprotein(a) testing: A survey of providers at the University of Pennsylvania Health System","author":"D\u2019Souza","year":"2024","journal-title":"J Clin Lipidol"},{"issue":"1, Supplement","key":"10.1016\/j.jacl.2025.04.200_bib0027","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1016\/j.chest.2020.03.012","article-title":"Cross-sectional studies: strengths, weaknesses, and recommendations","volume":"158","author":"Wang","year":"2020","journal-title":"Chest"},{"issue":"6","key":"10.1016\/j.jacl.2025.04.200_bib0028","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1007\/s40265-024-02046-z","article-title":"Therapeutic potential of lipoprotein(a) inhibitors","volume":"84","author":"Nicholls","year":"2024","journal-title":"Drugs"}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287425002776?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287425002776?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T17:43:51Z","timestamp":1765647831000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287425002776"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S1933287425002776"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2025.04.200","relation":{},"ISSN":["1933-2874"],"issn-type":[{"value":"1933-2874","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of lipid-lowering therapy in patients with elevated lipoprotein(a) levels","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Lipidology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacl.2025.04.200","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of National Lipid Association.","name":"copyright","label":"Copyright"}]}}